Elscint has reinforced its reputation for ongoing structural change by again reorganizingits nuclear medicine and CT/MRI sales and marketing groups. Changes announced March 1 are intended to give the units clearlydefined lines of responsibility,
Elscint has reinforced its reputation for ongoing structural change by again reorganizingits nuclear medicine and CT/MRI sales and marketing groups.
Changes announced March 1 are intended to give the units clearlydefined lines of responsibility, according to Donald J. Southard,vice president of sales and marketing. The key appointment isthe selection of John Ariatti as business unit director and actingwestern regional manager for CT/MRI.
Ariatti was formerly director of sales, marketing and customersupport for Otsuka Electronics in Fort Collins, CO. Prior to that,he was MRI marketing director and CT business unit manager forToshiba America Medical Systems.
Elscint Ltd., the parent company of Elscint, Inc., purchasedOtsuka's MRI business. Those assets have been renamed ElscintMR, Inc.
Israel Ohana has departed as nuclear medicine product managerand Southard has temporarily assumed that role. Southard joinedElscint as part of a 1994 restructuring effort, after servingas president and CEO of Serviscope, an independent service organizationin Wallingford, CT.
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
Study Shows Enhanced Diagnosis of Coronary Artery Stenosis with Photon-Counting CTA
July 10th 2025In a new study comparing standard resolution and ultra-high resolution modes for patients undergoing coronary CTA with photon-counting detector CT, researchers found that segment-level sensitivity and accuracy rates for diagnosing coronary artery stenosis were consistently > 89.6 percent.
Can CT-Based Deep Learning Bolster Prognostic Assessments of Ground-Glass Nodules?
June 19th 2025Emerging research shows that a multiple time-series deep learning model assessment of CT images provides 20 percent higher sensitivity than a delta radiomic model and 56 percent higher sensitivity than a clinical model for prognostic evaluation of ground-glass nodules.